Triple threat: radiation, chemo, and immunotherapy before breast cancer surgery

NCT ID NCT06914440

Recruiting now Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether giving a short course of targeted radiation (SBRT) followed by a reduced-dose chemotherapy (nab-paclitaxel) plus an immunotherapy drug (toripalimab) before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer. The study will enroll 27 participants with stage IIB to IIIC disease. The main goal is to see how many patients have no cancer remaining in the breast or lymph nodes at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiation therapy (SBRT), nab-paclitaxel, and toripalimab
What this could lead to: If it works, this combination could increase the chance of eliminating all cancer before surgery, potentially reducing recurrence risk for HR+/HER2- breast cancer patients.
What could go wrong: This is a small, early-phase trial with only 27 participants and no comparison group. The added radiation and immunotherapy may cause side effects, and the approach may not improve outcomes over standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Xijing Hospital Affiliated to Air Force Military Medical University
RECRUITING

Xi'an, Shannxi Province, 710032, China
Xijing Hospital Affiliated to Air Force Military Medical University
RECRUITING

Xi'an, Shannxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.